In Vivo Safety and Efficacy Platform for Immunotherapies

Advantages of Evaluating Immunomodulatory Therapeutics In Vivo in Hu-PBMC NSG Mice to Investigate GVHD

$0.34 - $3.00

Select Options

Comprehensive Immunodeficient Suite

$1.51 - $6.00

Select Options

Studying CRS In A Diverse Population FAQS

Select Options

CD34+ Hu-NSG-FLT3

$0.47 - $7.00

Select Options

HuPK A Humanized Platform for therapeutic antibody PK evaluation Field Guide

$1.68 - $10.00

Select Options

CRS Studies for CAR T Cell Therapy

$0.47 - $7.00

Select Options

Navigating the Complexity of Cancer Genomic Profiles to Deliver Precision Treatments

$0.47 - $7.00

Select Options

A New MHC Class I & II Deficient Platform Humanized With PBMC Has Delayed Xenogeneic GvHD

$0.81 - $9.00

Select Options